Quick Answer
Structure Therapeutics Inc. reported Operating Income of -$176.56 million for fiscal year 2025.
Structure Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$176.56M | -11.6% |
| 2024 | -$158.23M | -54.0% |
| 2023 | -$102.78M | -95.5% |
| 2022 | -$52.56M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$73.79M | -61.0% | -4.7% |
| June 30, 2025 | -$70.45M | -111.5% | -25.1% |
| March 31, 2025 | -$56.31M | -75.9% | -22.9% |
| September 30, 2024 | -$45.84M | -75.3% | -37.6% |
| June 30, 2024 | -$33.32M | -28.2% | -4.1% |
| March 31, 2024 | -$32.02M | -62.9% | -22.5% |
| September 30, 2023 | -$26.14M | -106.0% | -0.6% |
| June 30, 2023 | -$25.99M | -86.2% | -32.3% |
- Structure Therapeutics Inc. showed a decrease of -11.6% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Structure Therapeutics Inc.’s operating income has declined by 235.9% (from -$52.56 million to -$176.56 million).
- The most recent figure is from Structure Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: